Cyprotex
Tom Kaczka is a seasoned business development professional with extensive experience in the pharmaceutical and biotechnology sectors. Currently serving as a Business Development Manager at Cyprotex since February 2023, Tom previously held similar roles at XenoTech and managed client relationships and sales growth for Preclinical Drug Development services. Tom's background includes account management at National Jewish Health, where responsibilities spanned global client management for immunological testing, as well as roles at The Lubrizol Corporation and Univar, focusing on product offerings in pharmaceutical and personal care sectors. Early career experience at Cardinal Health, Aptuit, Quintiles, NexMed Inc, and Oread provided expertise in formulation science and regulatory affairs. Tom holds an MBA and an MA in Management from Webster University, along with a BA in Chemistry from Benedictine College.
This person is not in any offices
Cyprotex
Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development. * High-throughput ADME screening * Customised ADME assays * In silico ADME predictive modeling * In vitro toxicology